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　The stromal elements of bone marrow include cells, referred to as  mesenchymal stem 
cells (MSCs), that have the potential to differentiate into osteoblasts,  chondrocytes, 
myocytes, adipocytes and fibroblasts. It has been well established that bone morph-
ogenic protein 2 (BMP2) can induce orthotopic and ectopic bone formation. A  possible 
approach to producing bone in vivo involves the use of gene therapy in which  viral 
vectors are utilized to introduce the BMP2 gene into MSC. We reported that the 
introduction of recombinant adenovirus-mediated human BMP2 gene enabled MSC to 
produce BMP2 protein, to be differentiated into an osteoprogenitor line, and to induce 
bone formation in vitro. Regarding age and the osteogenic potential of MSC, we 
exhibited that the proliferation and osteogenic differentiation potential of MSCs from 
aged human was maintained. Our previous studies showed that MSCs engineered with 
the gene for BMP2 were capable of inducing autologous bone formation in several 
animal models. Moreover, we investigated whether allogeneic BMP2-engineered MSC 
would facilitate bone healing using rats with a femoral segment defect model. 
Engineered MSC completely repaired the bone defect. Abundant structual bone and 
well-developed cortical bone was noted by 8 weeks after transplantation. We also 
demonstrated that allogeneic BMP2-engineered MSC not only act as a gene deliverer, 
but also are directly involved in bone repair.
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